POSSIBLE SOLUTION FOR THE GLOBAL PROBLEM OF THE HIGH COST OF MEDICINES
Анотація
A new range of threats arose at the beginning of the 21st century, and the current global and national security systems could not respond effectively. Climate change threatens human health and well-being. Extreme weather events, food and water shortages, and the growth of infectious diseases increase the burden on healthcare systems. Progress in international health partnerships in 2022 has stalled and, in some cases, is reversing. The constant increase in the cost of medical services and medicines has a negative impact on the effectiveness of the functioning of national healthcare systems. Out-of-pocket healthcare costs cause financial hardship for more than 930 million people and push about 90 million into extreme poverty each year. If current trends continue, the World Health Organization predicts that by 2030, up to 5 billion people will be unable to access or afford health services. For further advancement in global health security and to ensure better health for all in a changing world, reducing the cost and guaranteeing access for indigent patients to innovative medicines for treating a wide range of life-threatening diseases is essential. To minimize the cost and ensure access to medicines, it is proposed to create international research centers for developing innovative medicines without patent protection with centralized funding and appropriate planning for high-level interdisciplinary fundamental and applied research based on the needs of healthcare systems worldwide.
Класифікація
Ідентифікатори
Рецензії (0)
Написати рецензіюРецензій ще немає. Будьте першим!
Схожі роботи
Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review
Схоже за: Biosimilars and Bioanalytical Methods · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
Development of Pharmacoeconomic Guidelines In Ukraine: Methodological Issues And Policy Implications
Схоже за: Biosimilars and Bioanalytical Methods · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
Shaping of the evidence-based substitution conceptual framework of the original medicines to generic counterparts in Ukraine
Схоже за: Biosimilars and Bioanalytical Methods · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
Current and Preferred Status on HTA Implementation: A Ukrainian Perspective
Схоже за: Biosimilars and Bioanalytical Methods · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
PMU54 DEVELOPMENT OF EXTENDED PHARMACY REIMBURSEMENT PROGRAM IN UKRAINE: EVIDENCE FROM THE ANALYSIS OF CENTRAL PROCUREMENT PROGRAMS
Схоже за: Biosimilars and Bioanalytical Methods · Health Systems, Economic Evaluations, Quality of Life · Pharmaceutical Economics and Policy
Comparative study of assortment of medical films presented in the pharmaceutical markets of Ukraine, USA and Poland
Схоже за: Biosimilars and Bioanalytical Methods · Pharmaceutical Economics and Policy